Kiniksa Pharmaceuticals International (KNSA) Current Leases (2019 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Current Leases for 8 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 59.08% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $4.0 million (up 59.08% YoY), and the FY2025 full-year result was $3.0 million, up 49.87% from the prior year.
• Current Leases climbed to $4.0 million in Q2 2026 per KNSA's latest filing, from $3.2 million in the prior quarter.
• Across five years, Current Leases topped out at $4.0 million in Q2 2026 and bottomed at $2.0 million in Q4 2024.
• Historically, Current Leases has averaged $2.8 million across 5 years, with a median of $2.6 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Current Leases plunged 34.55% in 2024, then jumped 59.08% in 2026.
• Over 5 years, Current Leases stood at $3.3 million in 2022, then plunged by 31.75% to $2.3 million in 2023, then dropped by 11.54% to $2.0 million in 2024, then jumped by 49.87% to $3.0 million in 2025, then jumped by 34.32% to $4.0 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $4.0 million, $3.2 million, and $3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.